COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,794 Articles (22,527 medRxiv, 8,267 bioRxiv)

Most recent first Previous |  Page 659: Articles 6581-6590  | Next

An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled study
Barrios, L., Garcia, L. A., Torales, J., Lin, M.-Y., Estrada, J. A. G., Estephan, L., Cheng, H.-Y., Chen, C., Lien, C. E.
10.1101/2022.07.14.22277617 — Posted: 2022-07-15
Tracing the international arrivals of SARS-CoV-2 Omicron variants after Aotearoa New Zealand reopened its border
Douglas, J., Winter, D., Ren, X., McNeill, A., Bunce, M., French, N., Hadfield, J., de Ligt, J., Welch, D., Geoghegan, J. L.
10.1101/2022.07.12.22277518 — Posted: 2022-07-15
Effect of Vitamin D3 supplementation vs. dietary-hygienic measures on SARS-COV-2 infection rates in hospital workers with 25-hydroxyvitamin D3 levels >20 ng/mL
Romero-Ibarguengoitia, M. E., Gutierrez-Gonzalez, D., Cantu-Lopez, C., Sanz-Sanchez, M. A., Gonzalez-Cantu, A.
10.1101/2022.07.12.22277450 — Posted: 2022-07-15
SARS-CoV-2 causes brain inflammation via impaired neuro-immune interactions
Oka, N., Shimada, K., Ishii, A., Kobayashi, N., Kondo, K.
10.1101/2022.07.13.499991 — Posted: 2022-07-15
Hospital admissions and mortality for acute exacerbations of COPD during the COVID-19 pandemic: a nationwide study in France
Poucineau, J., Delory, T., Lapidus, N., Hejblum, G., Chouaid, C., Le Coeur, S., Khlat, M.
10.1101/2022.07.11.22277259 — Posted: 2022-07-14
Nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on viral spike glycoprotein
Piacentini, S., Riccio, A., Santopolo, S., Pauciullo, S., Rossi, A., Rossignol, J.-F., Santoro, M. G.
10.1101/2022.07.13.499346 — Posted: 2022-07-13
Structural basis for the enhanced infectivity and immune evasion of Omicron subvariants
Li, Y., Shen, Y., Zhang, Y., Yan, R.
10.1101/2022.07.13.499586 — Posted: 2022-07-13
Pathobiology and dysbiosis of the respiratory and intestinal microbiota in 14 months old Golden Syrian hamsters infected with SARS-CoV-2
Seibert, B., Caceres, C. J., Carnaccini, S., Cardenas-Garcia, S., Gay, L. C., Ortiz, L., Geiger, G., de Souza Rajao, D. S., Ottesen, E., Perez, D. R.
10.1101/2022.07.13.499851 — Posted: 2022-07-13
Inducible Bronchus-Associated Lymphoid Tissue in SARS-CoV-2 Infected Rhesus Macaques
Ma, Z.-M., Olstad, K. J., Van Rompay, K. K. A., Iyer, S. S., Miller, C. J., Reader, J. R.
10.1101/2022.07.12.499813 — Posted: 2022-07-13
Efficient Tracing of the SARS-CoV-2 Omicron Variants in Santa Barbara County Using a Rapid Quantitative Reverse Transcription PCR Assay
Aralis, Z., Comer, S., Ansorg, H., Palmer, C., Smith, J., Feinstein, S., Fitzgibbons, L. N., Arias, C.
10.1101/2022.07.12.22277554 — Posted: 2022-07-13

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).